Literature DB >> 2373762

Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions.

M D Ellison1, R J Krieg, J T Povlishock.   

Abstract

The effects of systemic recombinant human interleukin-2 (rIL-2) infusion on cerebrovascular permeability to an endogenous circulating macromolecule, immunoglobulin G (IgG), were assessed in rats after single and multiple rIL-2 infusions. Ultrastructural detail of the cerebral vasculature and the related brain parenchyma was also examined for rIL-2-related changes following single and multiple infusions. Animals examined 6 and 24 h after a single rIL-2 infusion exhibited moderately increased permeability to IgG that was not observed in those animals examined 6 h after 5 days of rIL-2 infusion. Alterations of cerebrovascular morphology were evident as early as 6 h after a single infusion and were accompanied by occasional axonal degeneration and demyelination. Such structural changes persisted, becoming more widespread after 5 days of rIL-2 infusion, at which time they were associated with other neuronal as well as glial alterations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373762     DOI: 10.1016/0165-5728(90)90018-i

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Paradoxical sleep insomnia and decreased cholinergic neurons after myocardial infarction in rats.

Authors:  Thierno Madjou Bah; François Laplante; Boubacar Pasto Wann; Ron Sullivan; Guy Rousseau; Roger Godbout
Journal:  Sleep       Date:  2010-12       Impact factor: 5.849

2.  Combinational therapy using hypothermia and the immunophilin ligand FK506 to target altered pial arteriolar reactivity, axonal damage, and blood-brain barrier dysfunction after traumatic brain injury in rat.

Authors:  Yasutaka Oda; Guoyi Gao; Enoch P Wei; John T Povlishock
Journal:  J Cereb Blood Flow Metab       Date:  2010-12-15       Impact factor: 6.200

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping.

Authors:  A Pace; A Pietrangeli; L Bove; M Rosselli; M Lopez; B Jandolo
Journal:  Ital J Neurol Sci       Date:  1994-10

5.  Delayed neurotoxicity of intraventricular interleukin-2: a case report.

Authors:  C A Meyers; W K Yung
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

6.  Evaluation of the inflammatory response in sera from acute ischemic stroke patients by measurement of IL-2 and IL-10.

Authors:  Amit R Nayak; Rajpal S Kashyap; Hemant J Purohit; Dinesh Kabra; Girdhar M Taori; Hatim F Daginawala
Journal:  Inflamm Res       Date:  2009-04-02       Impact factor: 4.575

7.  In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

Authors:  M K Sharief; R Hentges; M Ciardi; E J Thompson
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

Review 8.  Pretreatment Cancer-Related Cognitive Impairment-Mechanisms and Outlook.

Authors:  Brennan Olson; Daniel L. Marks
Journal:  Cancers (Basel)       Date:  2019-05-16       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.